Navigation Links
AtriCure Appoints Mark A. Collar to its Board of Directors
Date:2/7/2008

WEST CHESTER, Ohio, Feb. 7 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, announced today the appointment of Mark A. Collar to the Company's Board of Directors. Mr. Collar recently retired from a distinguished career with The Procter & Gamble Company, including recently serving as President of the Global Pharmaceuticals and Personal Health business.

"We are pleased to add Mark to the Board of Directors of AtriCure," said Richard Johnston, Chairman of the Board of AtriCure, Inc. "We welcome Mark and his extensive, broad-based business experience to our board, specifically, his experience in the life sciences sector. We believe Mark will immediately contribute and bring value to AtriCure."

Mr. Collar, 54, joined Procter & Gamble in 1975 as a sales representative and assumed roles of progressive responsibility within their Health & Personal Care, Beauty Care, New Business Development, and Personal Health Care Products divisions. Mr. Collar moved to the Pharmaceuticals division in 1994 and was named President of Global Pharmaceuticals in 2002.

Mr. Collar is currently the Chairman of the Third Frontier Advisory Board, which provides direction for the state's 10 year $1.6 billion investment in high tech research, innovation, and company formation. He is also Vice Chairman and a Member of the Executive Committee for BioOhio, Inc., a non- profit organization which promotes the acceleration and growth of life science companies in Ohio. Further, Mr. Collar is a Trustee and Member of the Executive Committee for the Health Alliance, a leading hospital group serving the greater Cincinnati area.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) bipolar ablation system, including the new Isolator Synergy(TM) ablation clamps and the AtriCure multifunctional bipolar Pen, for the ablation, or destruction, of cardiac tissues during surgical procedures. Additionally, the FDA has cleared the AtriCure Pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure's products for the treatment of AF. AtriCure's left atrial appendage clip system has not been approved for commercial use. It is currently being used in clinical evaluations in Europe.

Contact:

AtriCure, Inc.

Julie A. Piton

Vice President and Chief Financial Officer

(513) 755-4561

jpiton@atricure.com


'/>"/>
SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
4. AtriCure to Present at ThinkEquity Partners 5th Annual Growth Conference
5. Published Results Using AtriCure Minimally Invasive Products
6. AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results
7. AtriCure Ranked 80th in Deloittes Technology Fast 500
8. AtriCure Reports Third Quarter 2007 Financial Results
9. AtriCure to Present at BMO Capital Markets 2007 Healthcare Conference
10. AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2007 Financial Results
11. WorldHeart Appoints David Pellone Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: